PMID- 20094042
OWN - NLM
STAT- MEDLINE
DCOM- 20110607
LR  - 20220321
IS  - 1930-739X (Electronic)
IS  - 1930-7381 (Linking)
VI  - 18
IP  - 12
DP  - 2010 Dec
TI  - Fumagillin reduces adipose tissue formation in murine models of nutritionally 
      induced obesity.
PG  - 2241-6
LID - 10.1038/oby.2009.503 [doi]
AB  - The effect of fumagillin (a methionine aminopeptidase-type 2 (Met-AP2) inhibitor, 
      with antiangiogenic properties) was investigated in murine models of diet-induced 
      obesity. Eleven-week-old male C57Bl/6 mice (group 1) were given fumagillin by 
      oral gavage at a dose of 1 mg/kg/day during 4 weeks while fed a high-fat diet 
      (HFD) (20.1 kJ/g), and control mice (group 2) received solvent and were pair-fed. 
      At the end of the experiment, body weights in group 1 were significantly lower as 
      compared to group 2 (P < 0.0005). The subcutaneous (SC) and gonadal (GON) fat 
      mass was also significantly lower in group 1 (P < 0.005 and P < 0.05, 
      respectively). Adipocytes were smaller in adipose tissues of mice in group 1, 
      associated with higher adipocyte density. Blood vessel density normalized to 
      adipocyte density was lower in group 1 adipose tissues. However, in mice with 
      established obesity monitored to maintain the same body weight and fat mass as 
      controls, short-term fumagillin administration was also associated with adipocyte 
      hypotrophy (P = 0.01) without affecting blood vessel size or density. Thus, 
      treatment with fumagillin impaired diet-induced obesity in mice, associated with 
      adipocyte hypotrophy but without marked effect on adipose tissue angiogenesis.
FAU - Lijnen, Henri R
AU  - Lijnen HR
AD  - Center for Molecular and Vascular Biology, KU Leuven, Leuven, Belgium. 
      roger.lijnen@med.kuleuven.be
FAU - Frederix, Liesbeth
AU  - Frederix L
FAU - Van Hoef, Berthe
AU  - Van Hoef B
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20100121
PL  - United States
TA  - Obesity (Silver Spring)
JT  - Obesity (Silver Spring, Md.)
JID - 101264860
RN  - 0 (Angiogenesis Inhibitors)
RN  - 0 (Anti-Obesity Agents)
RN  - 0 (Biological Products)
RN  - 0 (Cyclohexanes)
RN  - 0 (Dietary Fats)
RN  - 0 (Fatty Acids, Unsaturated)
RN  - 0 (Glycoproteins)
RN  - 0 (Sesquiterpenes)
RN  - 7OW73204U1 (fumagillin)
RN  - EC 3.4.11.- (Aminopeptidases)
RN  - EC 3.4.11.18 (Metap2 protein, mouse)
RN  - EC 3.4.11.18 (Methionyl Aminopeptidases)
SB  - IM
MH  - Adipose Tissue/blood supply/cytology/*drug effects
MH  - Aminopeptidases/antagonists & inhibitors
MH  - Angiogenesis Inhibitors/pharmacology/therapeutic use
MH  - Animals
MH  - Anti-Obesity Agents/pharmacology/*therapeutic use
MH  - Aspergillus fumigatus/*chemistry
MH  - Biological Products/pharmacology/therapeutic use
MH  - Body Fat Distribution
MH  - Body Weight/*drug effects
MH  - Cyclohexanes/pharmacology/*therapeutic use
MH  - Dietary Fats/*adverse effects
MH  - Fatty Acids, Unsaturated/pharmacology/*therapeutic use
MH  - Glycoproteins/antagonists & inhibitors
MH  - Male
MH  - Methionyl Aminopeptidases
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Obesity/blood/chemically induced/*drug therapy
MH  - Sesquiterpenes/pharmacology/therapeutic use
EDAT- 2010/01/23 06:00
MHDA- 2011/06/08 06:00
CRDT- 2010/01/23 06:00
PHST- 2010/01/23 06:00 [entrez]
PHST- 2010/01/23 06:00 [pubmed]
PHST- 2011/06/08 06:00 [medline]
AID - oby2009503 [pii]
AID - 10.1038/oby.2009.503 [doi]
PST - ppublish
SO  - Obesity (Silver Spring). 2010 Dec;18(12):2241-6. doi: 10.1038/oby.2009.503. Epub 
      2010 Jan 21.